What question did this study set out to answer?

The aim is to compare the effectiveness of two formulations of nepafenac in treating PCME post-cataract surgery.

June 12, 2026BMC OphthalmologyOpen Access

Comparison of topical nepafenac 0.1% and 0.3% for the treatment of pseudophakic cystoid macular edema following cataract surgery

View Full Paper

Ask AI

Bookmark

Authors

Retrospective study compares visual and anatomical outcomes of nepafenac in patients post-cataract surgery.

The aim is to compare the effectiveness of two formulations of nepafenac in treating PCME post-cataract surgery.
Retrospective comparative study included 97 eyes from 78 patients with PCME.
Patients received either 0.1% or 0.3% nepafenac after PCME diagnosis.
Best-corrected visual acuity and choroidal parameters assessed via optical coherence tomography.
Group-1 had significantly better mean BCVA at three months (0.056 ± 0.082 vs. 0.122 ± 0.135, p = 0.028).
At one month, Group-1 showed thinner central foveal subfield thickness compared to Group-2 (348.0 ± 96.5 vs. 387.9 ± 130.7, p = 0.047).
Group-1 had a higher rate of complete anatomical response at one month (60.0% vs. 38.1%, p = 0.033).

Çakmak et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark